Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 6/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22980532 | 0.84 | L3MBTL1 (0.44) | L3MBTL1ACHE | |
| SCHEMBL2828291 | 0.83 | L3MBTL1 (0.68) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 | |
| SCHEMBL370569 | 0.80 | L3MBTL1 (0.44) | L3MBTL1 | |
| SCHEMBL553834 | 0.79 | L3MBTL1 (0.73) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 | |
| SCHEMBL17723760 | 0.79 | L3MBTL1 (0.54) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 | |
| SCHEMBL31681673 | 0.79 | L3MBTL1 (0.67) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 | |
| Hydrochloric Acid SCHEMBL4758885 | 0.78 | L3MBTL1 (0.71) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 | |
| SCHEMBL29954606 | 0.77 | L3MBTL1 (0.65) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 | |
| SCHEMBL31352292 | 0.77 | L3MBTL1 (0.55) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 | |
| SCHEMBL31286462 | 0.76 | L3MBTL1 (0.69) | L3MBTL1HPGDSALKBH2PLA2G4AALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| EP-2595986-A2 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012009009-A2 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | L3MBTL1 4462/4885HPGDS 1398/4885ALKBH2 3485/4885 |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | L3MBTL1 4462/4885HPGDS 1398/4885ALKBH2 3485/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | L3MBTL1 4462/4885HPGDS 1398/4885ALKBH2 3485/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | L3MBTL1 4462/4885HPGDS 1398/4885ALKBH2 3485/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | L3MBTL1 4462/4885HPGDS 1398/4885ALKBH2 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.